

Releasing the Brakes on Cancer Immunotherapy

New England Journal of Medicine

373, 1490-1492

DOI: [10.1056/nejmp1510079](https://doi.org/10.1056/nejmp1510079)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immunotherapy and radiation therapy for malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2007, 6, 212-219.	1.3	31
2	The Paradox of Anti-cancer Agents and Recurring Emergence of Drug Resistance. <i>Journal of Biomedical Sciences</i> , 2016, 05, .	0.3	0
3	Potential role of immunotherapy in advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 21-30.	1.0	46
4	An update on clinical oncology for the non-oncologist. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 294-299.	0.3	2
5	Enrichment of Inflammatory IL-17 and TNF- α Secreting CD4+ T Cells within Colorectal Tumors despite the Presence of Elevated CD39+ T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. <i>Frontiers in Oncology</i> , 2016, 6, 50.	1.3	26
6	Targeting folate receptor alpha for cancer treatment. <i>Oncotarget</i> , 2016, 7, 52553-52574.	0.8	308
7	High-throughput genomic profiling of tumor-infiltrating leukocytes. <i>Current Opinion in Immunology</i> , 2016, 41, 77-84.	2.4	43
8	Immune-mediated respiratory adverse events of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 269-277.	1.1	39
9	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 255-264.	2.3	335
10	Update in Hematology and Oncology: Evidence Published in 2015. <i>Annals of Internal Medicine</i> , 2016, 164, W32.	2.0	0
11	Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 673-675.	1.1	9
12	Cancer immunotherapy: the beginning of the end of cancer?. <i>BMC Medicine</i> , 2016, 14, 73.	2.3	908
13	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
15	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
17	The PD-1/PD-L1 Axis in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 644-644.	2.5	4
18	Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. <i>Immunotherapy</i> , 2016, 8, 1097-1117.	1.0	58
19	Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1954-1961.	0.5	10
20	Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody. <i>Advanced Materials</i> , 2016, 28, 8912-8920.	11.1	286

#	ARTICLE	IF	CITATIONS
21	Reply: Disparities in Access to Lung Transplantation“More Than Meets the Eye. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 643-644.	2.5	0
22	Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 935-938.	2.3	1
23	Cancer Research in the 21st Century. Annals of Surgery, 2016, 264, 555-565.	2.1	0
24	The impact of personalized medicine of Type 2 diabetes mellitus in the global health context. Personalized Medicine, 2016, 13, 381-393.	0.8	3
25	Is allogeneic transplant for solid tumors still alive?. Bone Marrow Transplantation, 2016, 51, 751-752.	1.3	9
26	The Case for a Pre-Cancer Genome Atlas (PCGA). Cancer Prevention Research, 2016, 9, 119-124.	0.7	85
27	TIME for a successful cancer vaccine in NSCLC?. Lancet Oncology, The, 2016, 17, 131-132.	5.1	1
28	Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treatment Reviews, 2016, 45, 30-37.	3.4	242
29	Opportunities and challenges in combination gene cancer therapy. Advanced Drug Delivery Reviews, 2016, 98, 35-40.	6.6	64
30	Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis and Rheumatology, 2017, 69, 687-699.	2.9	101
31	Lymph Node Metastasis—Funded in part by the Nathanson/Rands Chair in Breast Cancer Research. Artwork by Kelly Rosso, MD, and Dhananjay Chitale, MD., 2017, , 235-261.		5
32	Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Oncologist, 2017, 22, 470-479.	1.9	244
33	New challenges in therapeutic vaccines against HIV infection. Expert Review of Vaccines, 2017, 16, 587-600.	2.0	28
34	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-“Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research, 2017, 77, 3540-3550.	0.4	327
35	Metabolic Instruction of Immunity. Cell, 2017, 169, 570-586.	13.5	871
36	Is autoimmunity the Achilles' heel of cancer immunotherapy?. Nature Medicine, 2017, 23, 540-547.	15.2	367
37	Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells. Cancer Research, 2017, 77, 4378-4388.	0.4	56
38	Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. Acta Pharmacologica Sinica, 2017, 38, 823-834.	2.8	65

#	ARTICLE	IF	CITATIONS
39	New agents on the horizon in gastric cancer. <i>Annals of Oncology</i> , 2017, 28, 1767-1775.	0.6	95
40	Clinical trials of CAR-T cells in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 166.	6.9	62
42	Nueva inmunoterapia y c�ncer de pulm�n. <i>Archivos De Bronconeumologia</i> , 2017, 53, 682-687.	0.4	8
43	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	1.0	30
44	Effects of Affordable Care Act Marketplaces and Medicaid Eligibility Expansion on Access to Cancer Care. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 168-174.	1.0	16
45	New Immunotherapy and Lung Cancer. <i>Archivos De Bronconeumologia</i> , 2017, 53, 682-687.	0.4	8
46	The dawn of ‘‘immune-revolution’’ in children: early experiences with checkpoint inhibitors in childhood malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1047-1053.	1.1	15
47	Evolution of Cancer Defense Mechanisms Across Species. , 2017, , 99-110.		15
48	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. <i>The Cochrane Library</i> , 2017, , .	1.5	1
49	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 730-749.	7.7	367
50	Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. <i>Journal of Palliative Medicine</i> , 2018, 21, 694-699.	0.6	9
51	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
52	Nanomaterial-assisted sensitization of oncotherapy. <i>Nano Research</i> , 2018, 11, 2932-2950.	5.8	19
53	DNA Nanostructure‐Based Systems for Intelligent Delivery of Therapeutic Oligonucleotides. <i>Advanced Healthcare Materials</i> , 2018, 7, e1701153.	3.9	56
54	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. <i>AAPS Journal</i> , 2018, 20, 66.	2.2	10
55	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non‐Small-Cell Lung Cancer: Where Do We Stand?. <i>Clinical Lung Cancer</i> , 2018, 19, 1-11.	1.1	48
56	A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. <i>Redox Biology</i> , 2018, 14, 316-327.	3.9	166
57	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278

#	ARTICLE	IF	CITATIONS
58	Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e177-e184.	1.1	6
59	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. <i>Hematologie</i> , 2018, 24, 183-193.	0.0	0
60	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. <i>Ochsner Journal</i> , 2018, 18, 370-376.	0.5	33
61	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. <i>Current Opinion in Lipidology</i> , 2018, 29, 381-388.	1.2	8
62	Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3613.	1.8	30
63	Immunotherapy Advances in Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 79.	1.3	5
64	Cytokine release syndrome: grading, modeling, and new therapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 121.	6.9	99
65	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5973-5989.	1.0	94
66	Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1401-1416.	1.6	28
67	Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells. <i>PLoS ONE</i> , 2018, 13, e0206182.	1.1	6
68	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 209-215.	2.0	29
69	Rheumatic immune-related adverse events from cancer immunotherapy. <i>Nature Reviews Rheumatology</i> , 2018, 14, 569-579.	3.5	162
70	Advances in geriatric oncology: a multidisciplinary perspective. <i>Tumori</i> , 2018, 104, 252-257.	0.6	6
71	Programmed Cell Death-1 Inhibitor-induced Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3144-3154.	1.8	156
72	Durvalumab for the treatment of non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 627-639.	1.0	38
73	Molecular therapies and precision medicine for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 599-616.	12.5	1,308
74	Current status and future directions of cancer immunotherapy. <i>Journal of Cancer</i> , 2018, 9, 1773-1781.	1.2	273
75	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. <i>A Cochrane Rapid Review. The Cochrane Library</i> , 2018, 7, CD012838.	1.5	11

#	ARTICLE	IF	CITATIONS
76	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. <i>Journal of Cancer</i> , 2018, 9, 205-212.	1.2	9
77	Considerations for development of therapies for cutaneous neurofibroma. <i>Neurology</i> , 2018, 91, S21-S30.	1.5	23
78	CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. <i>Journal of Hematology and Oncology</i> , 2018, 11, 41.	6.9	44
79	<p>A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4955-4973.	1.0	9
80	Synergistic combination of oncolytic virotherapy with CAR T-cell therapy. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 217-292.	0.9	15
81	Determinants of immunological evasion and immuncheckpoint inhibition response in non-small cell lung cancer: the genetic front. <i>Oncogene</i> , 2019, 38, 5921-5932.	2.6	27
82	Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2283.	2.2	56
83	Creatine uptake regulates CD8 T cell antitumor immunity. <i>Journal of Experimental Medicine</i> , 2019, 216, 2869-2882.	4.2	61
84	<p>Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1867-1877.	0.9	12
86	Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 20.	2.0	4
87	Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. <i>Autoimmunity Reviews</i> , 2019, 18, 805-813.	2.5	15
88	Immune checkpoint inhibitorâ€induced Type 1 diabetes: a systematic review and metaâ€analysis. <i>Diabetic Medicine</i> , 2019, 36, 1075-1081.	1.2	124
89	Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. <i>Cancer Letters</i> , 2019, 458, 123-135.	3.2	40
90	The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast. <i>American Journal of Clinical Pathology</i> , 2019, 152, 169-176.	0.4	10
91	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 860-865.	1.6	76
92	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 17.	6.9	80
94	Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. , 2019, 7, 344.		45
95	Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 149-152.	0.7	7

#	ARTICLE	IF	CITATIONS
96	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. <i>Advanced Functional Materials</i> , 2019, 29, 1806087.	7.8	21
97	Atezolizumab for the treatment of triple-negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1-5.	1.9	78
98	Nivolumab-induced aplastic anemia: A case report and literature review. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 221-225.	0.5	38
99	Detection of neoantigen-reactive T cell clones based on the clonal expansion using next-generation sequencing of T cell receptor β^2 complementarity-determining region 3. <i>Journal of Immunological Methods</i> , 2020, 476, 112679.	0.6	3
100	Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7295.	1.8	49
101	Application of Single-Cell Sequencing to Immunotherapy. <i>Urologic Clinics of North America</i> , 2020, 47, 475-485.	0.8	5
102	Editorial: Response and Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 607298.	1.3	1
103	Proscillaridin A inhibits hepatocellular carcinoma progression through inducing mitochondrial damage and autophagy. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 53, 19-28.	0.9	4
104	Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1381.	1.3	10
105	A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 4229-4236.	0.5	4
106	Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522096567.	0.5	5
107	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2967.	1.0	23
108	Achieving efficacious immunotherapy for patients with glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 909-911.	1.1	0
109	Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 428-440.	0.9	8
110	Nanozymes for Catalytic Cancer Immunotherapy. <i>ACS Applied Nano Materials</i> , 2020, 3, 4925-4943.	2.4	48
111	Engineered biomaterials for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 35-46.	3.1	52
112	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	1.3	10
113	Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4441.	1.8	20

#	ARTICLE	IF	CITATIONS
114	Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer—A Stimulating Partnership. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 360-368.	0.8	2
115	Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma. Cancer Immunology Research, 2020, 8, 479-492.	1.6	116
116	Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications. Future Oncology, 2020, 16, 497-506.	1.1	16
117	IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice. Biotechnology Letters, 2020, 42, 1113-1121.	1.1	17
118	Development and validation of an immune-related prognostic signature in lung adenocarcinoma. Cancer Medicine, 2020, 9, 5960-5975.	1.3	79
119	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	4.8	1,136
120	Interferons: role in cancer therapy. Immunotherapy, 2020, 12, 833-855.	1.0	26
121	Noncationic Material Design for Nucleic Acid Delivery. Advanced Therapeutics, 2020, 3, 1900206.	1.6	32
122	Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model. Scientific Reports, 2020, 10, 7078.	1.6	17
124	Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. Oncoimmunology, 2020, 9, 1746113.	2.1	15
125	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. International Journal of Radiation Oncology Biology Physics, 2021, 110, 35-52.	0.4	54
126	Artificial intelligence and the interplay between tumor and immunity. , 2021, , 211-235.		1
127	Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World Journal of Urology, 2021, 39, 1319-1329.	1.2	30
128	Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Supportive Care in Cancer, 2021, 29, 2029-2035.	1.0	7
129	Cancer Immunology and the Evolution of Immunotherapy. , 2021, , 3-29.		1
130	Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases. Annals of Translational Medicine, 2021, 9, 34-34.	0.7	22
131	Anesthesia and Cancer Recurrence. , 2021, , 13-41.		0
132	Gold digging: Searching for gut microbiota that enhances antitumor immunity. Journal of Cellular Physiology, 2021, 236, 5495-5511.	2.0	2

#	ARTICLE	IF	CITATIONS
133	A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 753-757.	1.1	6
134	Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 965-980.	1.3	12
135	PILE: a candidate prognostic score in cancer patients treated with immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1630-1636.	1.2	14
136	Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2389-2404.	3.3	17
137	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 693-703.	1.1	3
138	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4712.	1.8	14
139	Increased incidence of venous thromboembolism with cancer immunotherapy. <i>Med</i> , 2021, 2, 423-434.e3.	2.2	46
140	Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science. <i>Annual Review of Biomedical Engineering</i> , 2021, 23, 493-516.	5.7	4
141	Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy. <i>Nutrients</i> , 2021, 13, 1633.	1.7	15
142	Targeting monoamine oxidase A for T cell-based cancer immunotherapy. <i>Science Immunology</i> , 2021, 6, .	5.6	35
143	Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 619385.	1.3	12
144	Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 3530.	5.8	68
145	Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy. <i>Journal of Biomedical Science</i> , 2021, 28, 50.	2.6	5
146	Overview of implantable and injectable biomaterials in immunotherapy. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 16, 195-201.	0.1	0
147	Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. <i>Science Translational Medicine</i> , 2021, 13, eabc8188.	5.8	48
148	Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice. <i>Cancers</i> , 2021, 13, 4883.	1.7	15
149	Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination. <i>Immunoinformatics</i> , 2021, 1-2, 100004.	1.2	1
150	Chimeric antigen receptor T-cell therapy: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 369-375.	0.7	2

#	ARTICLE	IF	CITATIONS
151	Cell-to-cell interaction analysis of prognostic ligand-receptor pairs in human pancreatic ductal adenocarcinoma. <i>Biochemistry and Biophysics Reports</i> , 2021, 28, 101126.	0.7	7
152	A randomized, phase 1, placebo-controlled trial of APG157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes. <i>Cancer</i> , 2020, 126, 1668-1682.	2.0	33
153	New Emerging Molecules in Cancer Research Which Hold Promise in Current Era. , 2019, , 539-583.		1
154	Management of checkpoint inhibitor-associated renal toxicities. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 215-223.	0.6	6
155	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	2.1	33
156	Cancer Immunotherapy and Immunonutrition. <i>MOJ Anatomy & Physiology</i> , 2017, 3, .	0.2	1
157	T Cell Metabolism in Cancer Immunotherapy. <i>Immunometabolism</i> , 2020, 2, .	0.7	16
158	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
159	PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models. <i>Pharmaceuticals</i> , 2021, 14, 6.	1.7	15
160	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. <i>World Journal of Gastroenterology</i> , 2019, 25, 5773-5788.	1.4	69
161	Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients. <i>Journal of Biosciences and Medicines</i> , 2019, 07, 1-12.	0.1	1
162	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185
163	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 439-457.	2.3	564
164	Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond. <i>Cureus</i> , 2020, 12, e12204.	0.2	8
165	Systemic Therapy for Metastatic Pancreatic Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 106.	1.3	33
166	Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. <i>Human Cell</i> , 2022, 35, 199-213.	1.2	20
167	REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. <i>IssledovaniĀ I Praktika V Medicine</i> , 2017, 4, 51-65.	0.1	4
168	Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 155-179.	0.1	0

#	ARTICLE	IF	CITATIONS
170	Precision medicine in medical oncology: hope, disappointment and reality. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1427-1431.	1.4	4
171	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743724.	1.8	2
172	Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. <i>The Korean Journal of Pancreas and Biliary Tract</i> , 2020, 25, 72-82.	0.0	1
173	Basics of immunotherapy for epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102283.	0.6	4
174	Amplifying antitumor T cell immunity with versatile drug delivery systems for personalized cancer immunotherapy. <i>Medicine in Drug Discovery</i> , 2022, 13, 100116.	2.3	1
175	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
176	A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade. <i>Frontiers in Genetics</i> , 2022, 13, 706468.	1.1	0
177	PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2061396.	2.1	20
178	Target Therapy and Immunotherapy For Gastric Cancer - Recent Updates. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	1
179	Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy. <i>Thrombosis Research</i> , 2022, 213, S51-S57.	0.8	6
181	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
182	Immunotherapy: an alternative promising therapeutic approach against cancers. <i>Molecular Biology Reports</i> , 2022, 49, 9903-9913.	1.0	17
183	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 969-978.	1.2	9
184	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	23
185	The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	21
186	Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review. <i>Current Oncology</i> , 2022, 29, 7987-7993.	0.9	1
188	The Role of Immunotherapy in Renal Cell Carcinoma. , 2023, , 1-31.		0
189	Programmed Cell Death Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer: Findings from a tertiary care institute in western part of India. <i>Indian Journal of Tuberculosis</i> , 2023, , .	0.3	0

#	ARTICLE	IF	CITATIONS
191	Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy. Nano Letters, 2023, 23, 1904-1913.	4.5	9